UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,086	12/28/2005	Krishna Prasad Hanumanthappa	4544-051936	6434
28289 THE WEBB LA	7590 07/23/200 AW FIRM, P.C.	EXAMINER		
700 KOPPERS BUILDING			BAUSCH, SARAE L	
436 SEVENTH AVENUE PITTSBURGH, PA 15219			ART UNIT	PAPER NUMBER
			1634	
			MAIL DATE	DELIVERY MODE
			07/23/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



## **UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office**

DATE MAILED:

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.	
10540086	12/28/05	HANUMANTHAPPA ET AL.		4544-051936	
			EXAMINER		
THE WEBB LAW FIRI 700 KOPPERS BUILD	IŃG		SARAE BAUSCH		
436 SEVENTH AVENUE PITTSBURGH, PA 15219			ART UNIT	PAPER	
			1634	20080721	

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant should review the entire application and fully comply with all sequence rules. For example, the application fails to comply with the sequence rules because the specification discloses sequences of more than ten nucleotides, figure 5, and sequences of more than four amino acids (e.g. page 9) that are not in the sequence listing and do not have sequence identifiers. Additionally the specification refers to SEQ ID No. 1-N and 2-S (see pg. 16, pg 24) and it is unclear if these sequences are SEQ ID NO: 1 or some other sequence. Additionally the sequences listed on pages 25-26 are not in the sequence listing and conflict with the sequences in the sequence listing as SEQ ID No. 7 and 8 in the sequence listing are not the sequence names listed on page 25.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

/Sarae Bausch/ Primary Examiner Art Unit: 1634